EFTs: no more than two prior chemotherapy-containing lines in the metastatic/recurrent setting.
Has received no more than  previous lines of chemotherapy and has received at least two lines of chemotherapy in the metastatic setting.
No more than  lines of chemotherapy in the metastatic setting.
Must have received  or more prior lines or therapy in the metastatic setting
No more than  prior chemotherapy regimen in the metastatic setting for the phase  portion; patients in the phase  portion could have received any number of prior lines of therapy
Patients must have had two or more lines of prior therapy (chemo or hormonal) in the metastatic setting
More than  lines of chemotherapy in the metastatic setting; no limit on endocrine therapy lines; prior exposure to CDK/ inhibitor acceptable
More than  previous lines of therapy in the metastatic setting.
>  lines of prior chemotherapy in the metastatic setting
Any number of prior lines of chemotherapy in the metastatic setting is allowed
Patients must have had at least  lines of anti-HER directed therapies either in the metastatic or early-stage disease setting
Have received treatment with at least one or more lines of cytotoxic chemotherapy in the metastatic setting.
More than two prior lines of cytotoxic chemotherapy (e.g., gemcitabine, doxorubicin, capecitabine) for metastatic disease.
Part B: Subject must not have received any prior lines of chemotherapy in the metastatic setting (prior treatment with immunotherapy is allowed).
Patients with chemotherapy for metastatic disease (patients with - prior lines of chemotherapy for metastatic breast cancer [MBC])
More than two previous treatment lines of systemic antineoplastic therapies in the advanced setting
More than  prior lines of systemic antineoplastic therapies in the advanced setting
The patient must have received at least  and no more than  prior lines of treatment in the metastatic setting.
No more than  prior lines of systemic chemotherapy for metastatic urothelial cancer
Unlimited number of lines of endocrine therapy and up to two lines of cytotoxic chemotherapy in the metastatic setting (Phase Ib)
Unlimited number of lines of endocrine therapy and one line of cytotoxic chemotherapy in the metastatic setting (Phase II)
More than  prior lines of chemotherapy for metastatic breast cancer.
No more than two lines of prior cytotoxic chemotherapy in the recurrent/metastatic (palliative intent) treatment setting
More than two prior lines of cytotoxic chemotherapy in the recurrent/metastatic disease setting (palliative treatment intent)(excluding single agent use of an EGFR inhibitor)
More than three prior lines of cytotoxic chemotherapy for metastatic disease
Participants may have - prior lines of cytotoxic chemotherapy in the metastatic setting
Patients may not have received any cytotoxic chemotherapy for treatment in the metastatic setting
For patients in the dose-expansion cohort of the study, not more than two prior lines of cytotoxic chemotherapy in the metastatic setting
Participants must have already received or been intolerant to at least two lines of hormonal therapies (including the adjuvant or metastatic setting) or be appropriate candidates for chemotherapy
History cancer with no limitation on prior lines of therapy in the metastatic setting
One, , or  prior lines of chemotherapy for metastatic disease and with progression of disease on last treatment regimen.